An engineered nanoplatform inhibiting energy metabolism and lysosomal activity of tumor cells to multiply cisplatin-based chemotherapy

被引:1
|
作者
Jiang, Wei [1 ,3 ]
Tie, Zuoxiu [3 ]
Yu, Chi [2 ]
Chen, Yu [4 ]
Liu, Dan [2 ]
Li, Bin [1 ]
机构
[1] Guangxi Univ Sci & Technol, Med Coll, Dept Biochem & Mol Biol, Liuzhou 545005, Peoples R China
[2] Shenyang Univ Chem Technol, Coll Pharmaceut & Biol Engn, Shenyang 110142, Peoples R China
[3] Nanjing Univ, Coll Engn & Appl Sci, MOE Key Lab High Performance Polymer Mat & Technol, Nanjing 210033, Peoples R China
[4] Commonwealth Sci & Ind Res Org CSIRO Mfg, Clayton, Vic 3168, Australia
关键词
Energy metabolism; Cell dormancy; Lysosome; Glutathione; Cisplatin prodrug; DRUG; POLYMER;
D O I
10.1016/j.biomaterials.2023.122354
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Although inhibiting the energy metabolism of tumor cells has become an effective measure to enhance chemotherapy, tumor cells can still escape the lethal effect of chemotherapy by entering a dormancy state with low-energy expenditure. Herein, the glutathione (GSH)-responsive nanoplatform (C-A-D NPs) were constructed to inhibit energy metabolism and lysosomal activity of tumor cells, thereby forcing tumor cells to remain vulnerable to cisplatin. In this system, cisplatin prodrug was reduced to cisplatin by GSH, and D-peptide and apoptozole (Az) were released to inhibit the energy metabolism and autophagy-lysosome pathway of tumor cells. The suppressed autophagy-lysosome pathway prevents tumor cells from entering a low-energy dormancy state, resulting in the loss of resistance to the lethal effect of cisplatin with high-energy expenditure and insufficient energy supply. Such engineered nanoplatform effectively enhances the chemotherapeutic effect of cisplatin by inhibiting intracellular energy metabolism and lysosomal activity, showing great clinical prospects.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Durable complete remission after weekly docetaxel administration in a patient with mediastinal non-seminomatous germ-cell tumor refractory to cisplatin-based chemotherapy
    Berruti, A
    Saini, A
    Gorzegno, G
    Tampellini, M
    Borasio, P
    Dogliotti, L
    ANNALS OF ONCOLOGY, 2003, 14 (10) : 1589 - 1590
  • [42] Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy
    Shota Hamada
    Shiro Hinotsu
    Koji Kawai
    Shigeyuki Yamada
    Shintaro Narita
    Tomomi Kamba
    Hiroyuki Nishiyama
    Yoichi Arai
    Tomonori Habuchi
    Osamu Ogawa
    Koji Kawakami
    Supportive Care in Cancer, 2014, 22 : 2161 - 2166
  • [43] Antiemetic efficacy and safety of a combination of palonosetron, aprepitant, and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy
    Hamada, Shota
    Hinotsu, Shiro
    Kawai, Koji
    Yamada, Shigeyuki
    Narita, Shintaro
    Kamba, Tomomi
    Nishiyama, Hiroyuki
    Arai, Yoichi
    Habuchi, Tomonori
    Ogawa, Osamu
    Kawakami, Koji
    SUPPORTIVE CARE IN CANCER, 2014, 22 (08) : 2161 - 2166
  • [44] The peripheral immune status of granulocytic myeloid-derived suppressor cells correlates the survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy
    Shoji, Hirokazu
    Tada, Kohei
    Kitano, Shigehisa
    Nishimura, Takashi
    Shimada, Yasuhiro
    Nagashima, Kengo
    Aoki, Kazunori
    Hiraoka, Nobuyoshi
    Honma, Yoshitaka
    Iwasa, Satoru
    Takashima, Atsuo
    Kato, Ken
    Boku, Narikazu
    Honda, Kazufumi
    Yamada, Tesshi
    Heike, Yuji
    Hamaguchi, Tetsuya
    ONCOTARGET, 2017, 8 (56) : 95083 - 95094
  • [45] The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder
    Baras, Alexander S.
    Drake, Charles
    Liu, Jen-Jane
    Gandhi, Nilay
    Kates, Max
    Hoque, Mohamed O.
    Meeker, Alan
    Hahn, Noah
    Taube, Janis M.
    Schoenberg, Mark P.
    Netto, George
    Bivalacqua, Trinity J.
    ONCOIMMUNOLOGY, 2016, 5 (05):
  • [46] Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity
    Bellmunt, J.
    Gonzalez-Larriba, J. L.
    Prior, C.
    Maroto, P.
    Carles, J.
    Castellano, D.
    Mellado, B.
    Gallardo, E.
    Perez-Gracia, J. L.
    Aguilar, G.
    Villanueva, X.
    Albanell, J.
    Calvo, A.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2646 - 2653
  • [47] Expression of p53 and apoptosis of tumor cells in locally advanced cervical carcinoma after cisplatin based neoadjuvant chemotherapy
    Garzetti, GG
    Ciavattini, A
    Provinciali, M
    DiStefano, G
    Lucarini, G
    Goteri, G
    Biagini, G
    ANTICANCER RESEARCH, 1996, 16 (5B) : 3229 - 3234
  • [48] α-Lactalbumin-oleic acid complex kills tumor cells by inducing excess energy metabolism but inhibiting mRNA expression of the related enzymes
    Fang, B.
    Zhang, M.
    Ge, K. S.
    Xing, H. Z.
    Ren, F. Z.
    JOURNAL OF DAIRY SCIENCE, 2018, 101 (06) : 4853 - 4863
  • [49] Association between the peripheral immune status of granulocytic myeloid-derived suppressor cells and progression-free survival in advanced gastric cancer patients receiving cisplatin-based chemotherapy
    Shoji, H.
    Heike, Y.
    Tada, K.
    Kitano, S.
    Nishimura, T.
    Shimada, Y.
    Nagashima, K.
    Ito, A.
    Honma, Y.
    Iwasa, S.
    Okita, N.
    Takashima, A.
    Kato, K.
    Yamada, Y.
    Boku, N.
    Hamaguchi, T.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S465 - S466
  • [50] Prognostic Value of Programmed Death Ligand-1 Expression on Tumor-Infiltrating Immune Cells in Patients Treated with Cisplatin-Based Combination Adjuvant Chemotherapy Following Radical Cystectomy for Muscle-Invasive Bladder Cancer: A Retrospective Cohort Study
    Lee, Dong Hyeon
    Jeong, Jae Yong
    Song, Wan
    ONCOTARGETS AND THERAPY, 2021, 14 : 845 - 855